Epstein-Barr virus in Burkitt's lymphoma A role for latent membrane protein 2A

被引:25
作者
Bieging, Kathryn T. [1 ]
Swanson-Mungerson, Michelle [2 ]
Amick, Alexandra C. [1 ]
Longnecker, Richard [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA
[2] Midwestern Univ, Chicago Coll Osteopath Med, Dept Microbiol & Immunol, Downers Grove, IL 60515 USA
关键词
epstein-barr virus; burkitt's lymphoma; LMP2A; Myc; p53; apoptosis; viral oncogenesis; MEDIATED SIGNAL-TRANSDUCTION; MYC-INDUCED LYMPHOMAGENESIS; TUMOR-SUPPRESSOR P53; CELL RECEPTOR SIGNAL; TP53; GENE-MUTATIONS; C-MYC; TRANSGENIC MICE; AFRICAN CHILDREN; IN-VIVO; NASOPHARYNGEAL CARCINOMA;
D O I
10.4161/cc.9.5.10840
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Burkitt's lymphoma (BL) is characterized by translocation of the MYC gene to an immunoglobulin locus. Transgenic mouse models have been used to study the molecular changes that are necessary to bypass tumor suppression in the presence of translocated MYC. Inactivation of the p53 pathway is a major step to tumor formation in mouse models that is also seen in human disease. Human BL is often highly associated with Epstein-Barr virus (EBV). The EBV latency protein latent membrane protein 2A (LMP2A) is known to promote B cell survival by affecting levels of pro-survival factors. Using LMP2A transgenic mouse models, we have identified a novel mechanism that permits lymphomagenesis in the presence of an intact p53 pathway. This work uncovers a contribution of EBV to molecular events that have documented importance in BL pathogenesis, and may underlie the poorly understood link between EBV and BL.
引用
收藏
页码:901 / 908
页数:8
相关论文
共 97 条
[11]   TP53 MUTATIONS AND BREAST-CANCER PROGNOSIS - PARTICULARLY POOR SURVIVAL RATES FOR CASES WITH MUTATIONS IN THE ZINC-BINDING DOMAINS [J].
BORRESEN, AL ;
ANDERSEN, TI ;
EYFJORD, JE ;
CORNELIS, RS ;
THORLACIUS, S ;
BORG, A ;
JOHANSSON, U ;
THEILLET, C ;
SCHERNECK, S ;
HARTMAN, S ;
CORNELISSE, CJ ;
HOVIG, E ;
DEVILEE, P .
GENES CHROMOSOMES & CANCER, 1995, 14 (01) :71-75
[12]   Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis [J].
Bultema, R. ;
Longnecker, R. ;
Swanson-Mungerson, M. .
ONCOGENE, 2009, 28 (11) :1471-1476
[13]  
BURKITT D, 1961, CANCER-AM CANCER SOC, V14, P258, DOI 10.1002/1097-0142(196103/04)14:2<258::AID-CNCR2820140206>3.0.CO
[14]  
2-7
[15]   A SARCOMA INVOLVING THE JAWS IN AFRICAN CHILDREN [J].
BURKITT, D .
BRITISH JOURNAL OF SURGERY, 1958, 46 (197) :218-223
[16]   Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EμLMP2A transgenic mice [J].
Caldwell, RG ;
Brown, RG ;
Longnecker, R .
JOURNAL OF VIROLOGY, 2000, 74 (03) :1101-1113
[17]   Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals [J].
Caldwell, RG ;
Wilson, JB ;
Anderson, SJ ;
Longnecker, R .
IMMUNITY, 1998, 9 (03) :405-411
[18]   B cell receptor signal strength determines B cell fate [J].
Casola, S ;
Otipoby, KL ;
Alimzhanov, M ;
Humme, S ;
Uyttersprot, N ;
Kutok, JL ;
Carroll, MC ;
Rajewsky, K .
NATURE IMMUNOLOGY, 2004, 5 (03) :317-327
[19]  
Chao TY, 1997, CANCER-AM CANCER SOC, V80, P121, DOI 10.1002/(SICI)1097-0142(19970701)80:1<121::AID-CNCR16>3.0.CO
[20]  
2-#